Orris

Write the short note of epilepsy with etiop etio pathogenesis clinical manifestation non pharmacological and pharmacological treatment

Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Searching PubMed

epilepsy treatment guidelines antiseizure medications

I now have comprehensive information from the textbooks. Let me compile the complete short note on epilepsy.

Epilepsy - Short Note

Definition

Epilepsy is a chronic brain disease defined (ILAE 2014) by any of the following:
  1. At least two unprovoked (or reflex) seizures occurring more than 24 hours apart
  2. One unprovoked seizure with a probability of further seizures of at least 60% over the next 10 years
  3. Diagnosis of an epilepsy syndrome
A seizure is a transient event comprising symptoms and/or signs of abnormal, excessive, hypersynchronous neuronal activity in the brain.
  • Bradley and Daroff's Neurology in Clinical Practice, p. 2228

Etiopathogenesis

Etiology (ILAE Classification)

Epilepsy is not a single entity but a group of disorders. Causes are classified into six categories:
CategoryExamples
GeneticSCN1A mutation (Dravet syndrome), GABRG2 mutation, channelopathies; inherited or de novo mutations affecting ion channels
StructuralBrain tumors, cortical dysplasia, hippocampal sclerosis, post-stroke, post-traumatic, meningitis/encephalitis sequelae
MetabolicHypoglycemia, hypocalcemia, pyridoxine deficiency, mitochondrial disorders
ImmuneAutoimmune encephalitis (anti-NMDAR, LGI1, CASPR2 antibodies)
InfectiousNeurocysticercosis, CNS TB, herpes encephalitis (chronic sequelae)
UnknownNo identifiable cause (most common category)
Precipitating factors include: sleep deprivation, alcohol intake/withdrawal, illicit drug use, metabolic derangements (altered pH, electrolytes, blood glucose), fever, and stress.
  • Lippincott Illustrated Reviews: Pharmacology, p. 633

Pathogenesis

The fundamental mechanism of seizure generation involves a primary focus - a small population of neurons that fires abnormally and hypersynchronously.
Key mechanisms:
  1. Increased neuronal excitability - Imbalance between excitatory (glutamate, AMPA/NMDA receptor-mediated) and inhibitory (GABA-mediated) neurotransmission, tipping toward excessive excitation
  2. Voltage-gated channel dysfunction - Mutations or acquired changes in Na+, Ca2+, or K+ channels alter normal firing thresholds. For example, in Dravet syndrome, loss-of-function SCN1A mutations reduce sodium channel function in inhibitory interneurons, paradoxically increasing network excitability
  3. Paroxysmal depolarization shift (PDS) - Epileptic neurons undergo a large, sustained membrane depolarization followed by hyperpolarization; synchronous PDS in a neuronal population generates the ictal discharge seen on EEG
  4. Spread and generalization - Once initiated in the primary focus, the discharge spreads via synaptic and gap-junction connections to adjacent cortex (focal evolution) or subcortical structures (generalization via thalamocortical circuits)
  5. Epileptogenesis - The process by which normal brain tissue is transformed into chronically epileptogenic tissue, involving synaptic reorganization (mossy fiber sprouting in hippocampal sclerosis), neuroinflammation, and altered gene expression
  • Bradley and Daroff's Neurology in Clinical Practice, p. 2228-2245; Lippincott Illustrated Reviews: Pharmacology, p. 633

Clinical Manifestations

Classification of Seizures (ILAE 2017)

A. Focal Seizures (involving one hemisphere)
  • May occur with or without impaired awareness
  • Focal motor - clonic jerking, tonic posturing, epileptic spasms, automatisms of one body part
  • Focal non-motor - sensory (tingling, visual aura), autonomic (tachycardia, epigastric rising), or behavioral arrest
  • Focal to bilateral tonic-clonic - spreads to involve both hemispheres
B. Generalized Seizures (both hemispheres from onset, typically immediate loss of consciousness)
TypeKey Features
Tonic-clonic (grand mal)Loss of consciousness, tonic phase (sustained muscle contraction) then clonic phase (rhythmic jerking), followed by postictal confusion and exhaustion
Absence (petit mal)Brief (3-5 sec) abrupt staring with rapid eye blinking, onset age 3-5 years; characteristic 3 Hz spike-wave on EEG
MyoclonicBrief shock-like muscle jerks, often on awakening, onset at puberty or early adulthood
TonicSudden sustained extension muscle tone (<60 seconds)
ClonicRhythmic jerking, more impaired consciousness than myoclonic
Atonic (drop attacks)Sudden loss of muscle tone, risk of falls and injury; associated with Lennox-Gastaut syndrome
C. Unknown onset - when onset cannot be determined

Special Epilepsy Syndromes

  • West syndrome - Infantile spasms (clusters), hypsarrhythmia on EEG, developmental regression; peak onset 3-7 months
  • Dravet syndrome - Febrile status epilepticus in infancy, then multiple seizure types, caused by SCN1A mutation
  • Lennox-Gastaut syndrome - Multiple seizure types, slow spike-wave EEG, cognitive impairment

Postictal Features

Confusion, fatigue, headache, Todd's paralysis (transient focal weakness after a focal motor seizure)

EEG Findings

  • Epileptiform discharges (spikes, sharp waves) - present in up to 90% of epilepsy patients; 3 Hz spike-wave in absence epilepsy; photoparoxysmal response in photosensitive epilepsy
  • Interictal slowing may also be seen
  • Bradley and Daroff's Neurology in Clinical Practice, p. 2228-2248; Lippincott Illustrated Reviews: Pharmacology, p. 633-635

Treatment

Non-Pharmacological Treatment

  1. Ketogenic Diet (KD)
    • High-fat, low-carbohydrate diet inducing a state of ketosis
    • Shifts brain metabolism from glucose to ketone bodies; exact anticonvulsant mechanism unclear
    • Effective particularly in children with drug-resistant epilepsy, including Dravet syndrome and tuberous sclerosis
    • Variants: Modified Atkins diet, Low Glycemic Index Treatment
  2. Epilepsy Surgery
    • Indicated in drug-resistant (refractory) epilepsy (~30% of patients fail medications)
    • Resective surgery: Temporal lobectomy (most common; ~60-70% seizure-free), lesionectomy for structural lesions
    • Requires pre-surgical evaluation: video-EEG monitoring, MRI, neuropsychological testing, PET/SPECT, intracranial EEG if needed
    • Corpus callosotomy: Disconnects hemispheres; reduces drop attacks in Lennox-Gastaut
  3. Vagus Nerve Stimulation (VNS)
    • Implanted device delivers intermittent electrical stimulation to the left vagus nerve
    • Adjunctive therapy for focal and generalized drug-resistant epilepsy
    • Reduces seizure frequency by 50% in ~50% of patients; does not eliminate seizures in most
  4. Responsive Neurostimulation (RNS) / Deep Brain Stimulation (DBS)
    • RNS: Closed-loop device detects ictal activity and delivers responsive stimulation to the seizure focus
    • DBS: Continuous stimulation of the anterior nucleus of the thalamus
  5. Radiosurgery (Gamma Knife)
    • For specific lesions (e.g., hypothalamic hamartoma, cavernoma, small AVMs) not amenable to open surgery
  6. Lifestyle modifications
    • Regular sleep schedule (avoid sleep deprivation)
    • Avoid alcohol and recreational drugs
    • Stress management
    • Safety precautions (no swimming alone, driving restrictions per local law)
    • Women of childbearing age: folic acid supplementation, pre-conception counseling regarding teratogenic ASMs
  • Bradley and Daroff's Neurology in Clinical Practice, p. 1658-1661; Fitzpatrick's Dermatology, p. 3638-3643

Pharmacological Treatment

Principles of drug selection:
  • Based on seizure/epilepsy type, patient age, comorbidities, drug interactions, cost
  • Start with monotherapy at low dose; titrate to seizure control or limiting toxicity
  • If first drug fails, try a second monotherapy
  • Combination (polytherapy) is used if two sequential monotherapies fail
  • ~70% of patients achieve seizure freedom with medications
Mechanisms of action of antiseizure medications (ASMs):
  1. Blockade of voltage-gated Na+ channels (stabilizes inactive state) - Phenytoin, Carbamazepine, Lamotrigine, Oxcarbazepine, Valproate, Lacosamide
  2. Blockade of voltage-gated Ca2+ channels (T-type) - Ethosuximide, Valproate
  3. Enhancement of GABAergic inhibition
    • GABA-A potentiation: Benzodiazepines, Phenobarbital, Clobazam
    • Block GABA reuptake: Tiagabine
    • Inhibit GABA transaminase: Vigabatrin
  4. Inhibition of glutamate/AMPA transmission - Perampanel, Topiramate, Felbamate
  5. Synaptic vesicle protein SV2A binding (modulates neurotransmitter release) - Levetiracetam, Brivaracetam
  6. Multiple mechanisms - Valproate, Topiramate, Zonisamide
Drug selection by seizure type:
Seizure TypeFirst-Line ASMsAvoid
Focal (all subtypes)Carbamazepine, Lamotrigine, Levetiracetam, Oxcarbazepine, Lacosamide-
Generalized tonic-clonicValproate, Lamotrigine, Levetiracetam, TopiramateCarbamazepine*, Oxcarbazepine*
AbsenceEthosuximide, Valproate, LamotrigineCarbamazepine, Phenytoin
MyoclonicValproate, Levetiracetam, ClonazepamCarbamazepine, Phenytoin, Gabapentin
Atonic/Tonic (LGS)Valproate, Lamotrigine, Clobazam, Rufinamide, Felbamate-
Infantile spasmsACTH, Vigabatrin, Prednisone-
*May worsen generalized epilepsies
Key individual drugs:
DrugKey Feature
ValproateBroad-spectrum; teratogenic (neural tube defects); avoid in women of childbearing age
CarbamazepineFirst-line for focal seizures; enzyme inducer; risk of hyponatremia; Stevens-Johnson syndrome (HLA-B*1502 in Asians)
LamotrigineBroad-spectrum; preferred in women; risk of serious rash if dose escalated too fast; increased clearance by enzyme inducers
LevetiracetamMinimal drug interactions; behavioral side effects (irritability, aggression)
PhenytoinLow cost; zero-order kinetics (nonlinear PK); gingival hyperplasia, hirsutism, osteoporosis; enzyme inducer
EthosuximideAbsence seizures only; T-type Ca2+ channel blocker
PhenobarbitalEffective, low cost; sedation, cognitive effects; enzyme inducer; risk of dependence
TopiramateBroad-spectrum; cognitive side effects ("dopamax"), weight loss, oligohidrosis, kidney stones
ClonazepamMyoclonic and absence seizures; tolerance develops
Status Epilepticus (emergency):
  • Lorazepam IV (first-line benzodiazepine)
  • Followed by IV Phenytoin/Fosphenytoin or Levetiracetam or Valproate
  • Refractory SE: Propofol, Midazolam, or Phenobarbital infusion
  • Lippincott Illustrated Reviews: Pharmacology, p. 633-657; Bradley and Daroff's Neurology in Clinical Practice

Summary Table

AspectKey Points
Definition≥2 unprovoked seizures >24 hrs apart, or 1 seizure with ≥60% recurrence risk
EtiologyGenetic, structural, metabolic, immune, infectious, unknown
PathogenesisPDS, imbalanced GABA/glutamate, ion channel dysfunction, thalamocortical spread
Focal seizuresUnilateral onset, ± impaired awareness, may generalize
Generalized seizuresTonic-clonic, absence, myoclonic, tonic, clonic, atonic
Non-pharm RxKetogenic diet, epilepsy surgery, VNS, RNS/DBS, lifestyle measures
Pharmacological RxNa+ blockers, Ca2+ blockers, GABAergic drugs, SV2A binders; monotherapy first
Drug-resistant~30% of patients; consider surgery evaluation
Sources: Bradley and Daroff's Neurology in Clinical Practice; Lippincott Illustrated Reviews: Pharmacology, 16th ed.; Goodman & Gilman's Pharmacological Basis of Therapeutics

Short answer

Epilepsy - Short Answer

Definition

Epilepsy is a chronic brain disorder characterized by ≥2 unprovoked seizures occurring >24 hours apart, or one seizure with ≥60% risk of recurrence over 10 years.

Etiopathogenesis

Causes (ILAE categories):
  • Genetic - ion channel mutations (e.g., SCN1A in Dravet syndrome)
  • Structural - head trauma, stroke, tumors, hippocampal sclerosis
  • Metabolic - hypoglycemia, hypocalcemia, pyridoxine deficiency
  • Infectious - neurocysticercosis, CNS TB
  • Immune - autoimmune encephalitis
  • Unknown - most common
Pathogenesis: Abnormal hypersynchronous firing of a neuronal focus due to:
  • Imbalance between excitatory (glutamate) and inhibitory (GABA) neurotransmission
  • Dysfunction of voltage-gated Na+/Ca2+/K+ channels
  • Spread via thalamocortical circuits → focal or generalized seizure

Clinical Manifestations

TypeFeatures
FocalOne hemisphere; ± impaired awareness; may generalize
Tonic-clonicLoss of consciousness → tonic → clonic phases → postictal confusion
Absence3-5 sec staring + eye blinking; 3 Hz spike-wave on EEG
MyoclonicBrief muscle jerks, on awakening
AtonicSudden loss of tone; drop attacks
TonicSustained muscle stiffness <60 sec

Non-Pharmacological Treatment

  1. Ketogenic diet - high-fat, low-carb; for drug-resistant cases
  2. Epilepsy surgery - temporal lobectomy, lesionectomy (refractory epilepsy)
  3. Vagus nerve stimulation (VNS) - implanted device, adjunctive
  4. Responsive neurostimulation (RNS) / Deep brain stimulation
  5. Lifestyle - regular sleep, avoid alcohol/stress, safety precautions

Pharmacological Treatment

Principle: Start monotherapy; add second agent if needed.
Seizure TypeDrug of Choice
FocalCarbamazepine, Lamotrigine, Levetiracetam
Tonic-clonicValproate, Lamotrigine, Levetiracetam
AbsenceEthosuximide, Valproate
MyoclonicValproate, Levetiracetam
Status epilepticusLorazepam IV → Phenytoin/Levetiracetam IV
Mechanisms: Na+ channel blockade, Ca2+ channel blockade, GABA enhancement, glutamate inhibition, SV2A modulation.

Stroke ka isi tarah se short answer

Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
I now have sufficient information. Here is the complete short answer on Stroke:

Stroke - Short Answer

Definition

Stroke is a sudden onset focal neurological deficit due to interruption of blood supply to the brain, lasting >24 hours (or leading to death), caused by either ischemia or hemorrhage.
  • TIA (Transient Ischemic Attack) - Same mechanism but deficit resolves within 24 hours (usually <1 hour); high early risk of stroke.

Types

TypeFrequency
Ischemic stroke~85%
Hemorrhagic stroke (ICH / SAH)~15%

Etiopathogenesis

Risk Factors

  • Hypertension (single most important modifiable risk factor)
  • Atrial fibrillation, valvular heart disease
  • Diabetes mellitus, hypercholesterolemia
  • Smoking, obesity, sedentary lifestyle
  • Prior stroke/TIA, age, family history
  • Oral contraceptives, hypercoagulable states

Pathogenesis

A. Ischemic Stroke (3 main mechanisms):
  1. Thrombosis - Atherosclerosis of large vessels (carotid, vertebrobasilar) or small perforating vessels (lacunar infarcts); plaque rupture → thrombus → vessel occlusion
  2. Embolism - Cardioembolism (atrial fibrillation, MI, prosthetic valves) or artery-to-artery embolism; sudden occlusion of distal vessel
  3. Hemodynamic - Severe hypotension causing watershed infarction
Core mechanism: Vessel occlusion → reduced cerebral blood flow → ischemic penumbra (at-risk but salvageable tissue) surrounds irreversible infarct core → neuronal death due to ATP depletion, excitotoxicity (glutamate excess), Ca2+ influx, oxidative stress, and apoptosis
B. Hemorrhagic Stroke:
  • ICH - Hypertension causes lipohyalinosis of small vessels → rupture → hematoma; also amyloid angiopathy, AVM
  • SAH - Berry aneurysm rupture → blood in subarachnoid space

Clinical Manifestations

General features: Sudden onset, focal neurological deficit
TerritoryClinical Features
MCA (middle cerebral artery)Contralateral hemiplegia + hemisensory loss (face and arm > leg), aphasia (dominant hemisphere), neglect (non-dominant)
ACA (anterior cerebral artery)Contralateral hemiplegia (leg > arm), frontal lobe features, urinary incontinence
PCA (posterior cerebral artery)Contralateral homonymous hemianopia, thalamic sensory loss
Brainstem / BasilarDiplopia, dysphagia, dysarthria, crossed deficits, locked-in syndrome
LacunarPure motor hemiparesis, pure sensory stroke, ataxic hemiparesis, dysarthria-clumsy hand
ICHSudden severe headache, vomiting, rapid deterioration, focal deficits
SAH"Thunderclap" worst headache of life, meningism, photophobia
Associated features: Headache (25-30% of ischemic strokes), seizures (3-10%), altered consciousness

Non-Pharmacological Treatment

  1. Stroke unit care - Dedicated multidisciplinary stroke unit reduces mortality and disability
  2. Mechanical thrombectomy - Endovascular clot removal for large-vessel occlusion; up to 24 hours from onset (with perfusion imaging selection); highly effective
  3. Carotid endarterectomy (CEA) - For symptomatic carotid stenosis >70%; reduces recurrent stroke
  4. PFO closure - Endovascular closure for cryptogenic stroke with patent foramen ovale
  5. Rehabilitation - Physiotherapy, speech therapy, occupational therapy; begin early
  6. Lifestyle modification - BP control, smoking cessation, weight loss, regular exercise, diabetic control

Pharmacological Treatment

Acute Ischemic Stroke

DrugUse
IV Alteplase (tPA) 0.9 mg/kgWithin 4.5 hours of onset; restores perfusion; contraindicated if hemorrhage or >4.5 hrs
Aspirin 300 mgWithin 48 hrs (if no thrombolysis); then 75-150 mg/day long-term

Secondary Prevention

ConditionDrug
Non-cardioembolic strokeAntiplatelet: Aspirin, Clopidogrel, or Aspirin + Dipyridamole
Atrial fibrillationAnticoagulation: Warfarin (INR 2-3) or DOACs (Apixaban, Rivaroxaban, Dabigatran)
HypertensionThiazides, ACE inhibitors (target <130/80 mmHg)
DyslipidemiaStatin - Atorvastatin 80 mg/day (target LDL <70 mg/dL)
DiabetesGlycemic control; Pioglitazone if prediabetes/insulin resistance

Hemorrhagic Stroke (ICH)

  • Immediate BP lowering (target <140 mmHg)
  • Reverse anticoagulation (Vitamin K, FFP, PCC for warfarin)
  • Surgical evacuation for cerebellar ICH >3 cm or herniation
  • Nimodipine (for SAH - prevents vasospasm)

FAST Mnemonic (Recognition)

  • Face drooping
  • Arm weakness
  • Speech difficulty
  • Time to call emergency
Sources: Harrison's Principles of Internal Medicine 22E; Neuroanatomy through Clinical Cases 3rd Ed.; Fuster & Hurst's The Heart 15th Ed.
This is a shared conversation. Sign in to Orris to start your own chat.